These cardiovascular shifts may manifest as pressure headaches or migraines, especially if you have a personal or family history of migraine disorder
The core difference is how many gut hormone pathways each drug uses
Approximately 25% of tirzepatide users reported any headache, while only 15% reported severe headaches requiring intervention
Genetics, metabolic history, starting weight, duration of treatment, and lifestyle factors all play roles
Finally, considering the nature of subgroup analyses and the risk of false positive effects with a large number of comparisons [41], any conclusions should be interpreted cautiously and in the context of all available data in the literature
FDA remains committed to facilitating the development and approval of additional safe and effective therapies for adults with obesity or overweight. Statistics show that around 70% of American adults either have obesity or are overweight